Welcome back to RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers. In Part 2 of our Psoriatic Arthritis ACR wrap-up series, host Amanda Mixon, PA-C, and guest Daric Mueller, PA-C, explore new data from ACR Convergence 2024 that could change how we think about long-term outcomes in PsA care.

In this episode, we examine two important abstracts with major clinical implications:

Does smoking impact biologic drug retention in PsA? Daric dives into a large European cohort study evaluating how smoking and BMI affect the durability of secukinumab, revealing a notable link between smoking and increased treatment discontinuation—echoing similar patterns seen in TNF inhibitors.

Are certain PsA therapies more cardioprotective than others? Amanda breaks down a VA multi-center cohort study analyzing the effect of systemic immunosuppressive therapy on cardiovascular risk in PsA patients. The findings suggest that IL-17 and IL-23 pathway inhibitors may offer superior protection against cardiovascular events compared to traditional treatments, raising questions about how we approach comorbidity management in inflammatory arthritis.

This episode is packed with practical takeaways for advanced practice providers who are managing PsA patients with comorbid conditions like smoking, obesity, and cardiovascular disease. Amanda and Derek also share real-world strategies to enhance patient care, from baseline labs to interdisciplinary referrals.

Stay tuned for Part 3, where we’ll continue reviewing the most relevant PsA abstracts from ACR Convergence 2024.

#PsoriaticArthritis #ACRConvergence2024 #Secukinumab #CardiovascularRisk #IL17Inhibitors #SmokingCessation #RheumatologyPodcast #AdvancedPracticeProviders #RhAPP #BiologicTherapy #PsAComorbidities #PrecisionMedicine #RheumatologyEducation